Advertisement


Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Advertisement